Identification of Inhibitors of the Leishmania cdc2-Related Protein Kinase CRK3

Laura A. T. Cleghorn, Andrew Woodland, Iain T. Collie, Leah S. Torrie, Neil Norcross, Torsten Luksch, Chido Mpamhanga, Roderick G. Walker, Jeremy C. Mottram, Ruth Brenk, Julie A. Frearson, Ian H. Gilbert, Paul G. Wyatt (Lead / Corresponding author)

    Research output: Contribution to journalArticle

    37 Citations (Scopus)
    7 Downloads (Pure)

    Abstract

    New drugs are urgently needed for the treatment of tropical parasitic diseases such as leishmaniasis and human African trypanosomiasis (HAT). This work involved a high-throughput screen of a focussed kinase set of similar to 3400 compounds to identify potent and parasite-selective inhibitors of an enzymatic Leishmania CRK3-cyclin 6 complex. The aim of this study is to provide chemical validation that Leishmania CRK3-CYC6 is a drug target. Eight hit series were identified, of which four were followed up. The optimisation of these series using classical SAR studies afforded low-nanomolar CRK3 inhibitors with significant selectivity over the closely related human cyclin dependent kinase CDK2.

    Original languageEnglish
    Pages (from-to)2214-2224
    Number of pages11
    JournalChemMedChem
    Volume6
    Issue number12
    DOIs
    Publication statusPublished - 9 Dec 2011

    Keywords

    • CRK3
    • cyclin-dependent cdc2-related kinases
    • leishmaniasis
    • triazolopyridines
    • ureas
    • CYCLIN-DEPENDENT KINASE
    • TRYPANOSOMA-BRUCEI
    • 3-AMINOPYRAZOLE INHIBITORS
    • ANTITUMOR AGENTS
    • DISCOVERY
    • MEXICANA
    • DISEASES

    Cite this